Cardiovascular & hematological disorders drug targets最新文献

{"title":"Preface.","authors":"Pietro Scicchitano","doi":"10.2174/011871529X413132250523074035","DOIUrl":"https://doi.org/10.2174/011871529X413132250523074035","url":null,"abstract":"","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144183495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiopulmonary and Urine Electrolyte Changes in Healthy Males Exposed to Two Distinct Anaerobic Exercises.","authors":"Esther Oluwasola Aluko, Mary Emmanuel Etim, Favour Jerome Azunobi, Ekpono-Abasi Ubong Robinson, Uku Etim Ekpenyong","doi":"10.2174/011871529X369260250512024353","DOIUrl":"https://doi.org/10.2174/011871529X369260250512024353","url":null,"abstract":"<p><strong>Background: </strong>Anaerobic exercise, characterized by short bursts of high-intensity activity such as weightlifting, sprinting, and high-intensity interval training (HIIT), has been documented to influence the body physiology.</p><p><strong>Objective: </strong>The study investigated the acute impact of weightlifting and rope jumping exercise sessions on blood pressure, pulse rate, blood glucose, body temperature, pulmonary indices, and urine creatinine and electrolyte levels in healthy male subjects.</p><p><strong>Methods: </strong>Twenty participants, aged 18-25, were randomly assigned to the control group (n=10) and the exercise group (n=10). The control group watched exercise videos of weightlifting and rope jumping, respectively. The anaerobic exercise group performed weightlifting and rope jumping exercise sessions, respectively. Before the commencement of the experiment, the participants were given a 15-minute rest, and their blood pressure, body temperature, and blood glucose were measured. Then they were given 600 mL of water and 15 g of glucose for hydration and energy. After 45 minutes, their cardiovascular indices, blood glucose, body temperature, pulmonary indices, and urine sample for assessment of urine electrolyte and creatinine levels were taken. After that, the control group watched a video of people engaged in weight lifting, and the exercise group lifted 6 kg dumbbells (3 kg per arm) for 15 minutes with a 20-second break period after every 2 minutes of performing the exercise or watching the video. After the first session, a 30- minute recuperation period was given before the commencement of the second session (rope jumping). The same procedure was repeated in the second session. Blood pressure, pulse rate, blood glucose, and body temperature were measured immediately after the first session, 15, 30 minutes after the first session, immediately after the second session, 15, and 30 minutes after the second session. Pulmonary indices and urine samples were taken immediately after the first session, 30 minutes after the first session, immediately after the second session, and 30 minutes after the second session.</p><p><strong>Results: </strong>The results showed a significant increase in systolic blood pressure, mean arterial pressure, pulse rate, and body temperature; however, there was no significant difference in diastolic blood pressure, lung function parameters, or blood glucose in the exercise group compared to the control group. In addition, the exercise group showed a significant increase in urine sodium and potassium levels, as well as a significant decrease in urine creatinine level, at the end of the 30- minute recuperation period compared to the control group.</p><p><strong>Conclusion: </strong>The study demonstrated that weightlifting and rope jumping exercise sessions significantly increased blood pressure, pulse rate, and body temperature, but had no significant effect on lung function and blood glucos","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ranolazine: An Established Anti-Anginal Drug with Emerging Antidiabetic Potential Supported by Preclinical and Clinical Evidence.","authors":"Konstantinos N Tentolouris, Ioanna A Anastasiou, Iordanis Mourouzis, Costantinos Pantos, Nikolaos Tentolouris","doi":"10.2174/011871529X356362250324080014","DOIUrl":"https://doi.org/10.2174/011871529X356362250324080014","url":null,"abstract":"<p><strong>Background: </strong>High blood glucose levels are a hallmark of Diabetes Mellitus (DM), which is classified as a metabolic disease. DM is closely associated with various Cardiovascular Disease (CVD) risk factors, and poor glycemic control is known to elevate the risk of developing CVD. Ranolazine, a novel anti-anginal medication, has demonstrated cardioprotective effects, making it an important agent in the management of heart-related complications in diabetic patients. The mechanism underlying the anti-ischemic effect of ranolazine primarily involves the blockade of the cardiac isoform of voltage-gated Sodium Channels (NaChs), specifically Nav1.5. By inhibiting the late Sodium Current (INa, late), ranolazine helps stabilize cardiac function and reduce ischemic episodes. Recent large Randomized Controlled Trials (RCTs) have shown that ranolazine significantly reduces levels of glycosylated hemoglobin (HbA1c), which is a critical marker for glycemic control. This dual action of ranolazine in improving both cardiac performance and glycemic control positions it as a valuable therapeutic option in the management of patients with DM and cardiovascular risk.</p><p><strong>Objectives: </strong>This review aims to provide a comprehensive overview of the preclinical and clinical research concerning ranolazine's potential as an antidiabetic agent. By examining existing studies, we explore the drug's mechanisms of action, its impact on glycemic control, and its role in managing DM-related cardiovascular complications. Through the available data, we highlight the emerging evidence supporting ranolazine's use beyond its traditional role as an anti-anginal medication, as well as its promising implications for DM management.</p><p><strong>Methods: </strong>Using the terms ranolazine, DM, beta-cells, alpha cells, and preclinical and clinical trials, an EMBASE search for English language articles was conducted from 1979 to 2024.</p><p><strong>Results: </strong>Ranolazine has demonstrated a well-tolerated glucometabolic action and positively regulates glucose levels in individuals with DM. A meta-analysis has revealed that ranolazine effectively improves HbA1c levels without increasing the risk of hypoglycemia, offering significant advantages for patients with type 2 Diabetes Mellitus (T2DM) and stable angina. In addition to its effects on glycemic control, ranolazine has been shown to lower both baseline and postprandial glucagon levels in preclinical trials. This reduction in glucagon is associated with a decrease in hyperglycemia, suggesting that the blockade of Sodium Channels (NaChs) is integral to the glucose-lowering effects of ranolazine. Overall, these findings support the potential of ranolazine as a beneficial treatment option for managing glucose levels in diabetic patients, particularly those with concurrent cardiovascular conditions.</p><p><strong>Conclusion: </strong>A novel approach for treating T2DM could involve selective Nav1.3 block","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144047233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular and Immunometabolic Landscape of Erythrophagocytosis-induced Ferroptosis.","authors":"Charalampos Papadopoulos","doi":"10.2174/011871529X370553250322095430","DOIUrl":"https://doi.org/10.2174/011871529X370553250322095430","url":null,"abstract":"<p><p>Erythrocytes constitute the main cell type of the blood, contain the majority of the iron in the body, and have a high turnover rate. Erythrocyte death and subsequent degradation lead to ferroptosis. In this context, modifications of the erythrocyte plasma membrane lipidome are instrumental to the phenomenon. Thus, phospholipase A2, phospholipase D, lysophospholipase D, sphingomyelinase, ceramidase, and sphingosine kinase acting together orchestrate a major membrane structural rearrangement, leading to phosphatidylserine exposure, reduced deformability, and band 3 clustering. Band 3 clustering may lead to antibody and complement opsonization, CD47 conformational change, and phosphatidylserine exposure. Meanwhile, arginine, glutamine, and adenosine metabolism modulate the anti-oxidant capacity of erythrocytes, thus impacting phosphatidylserine exposure and chemokine release. Metabolism-induced augmented erythrophagocytosis accompanied by insufficient upregulation of heme oxygenase-1 and iron retention due to inflammatory signals lead to iron-dependent lipid peroxidation. Neudesin, interleukin 33, interleukin 18, TNF-α, interleukin 6, prostaglandins, epinephrin, itaconate, and hepcidin influence the capacity of the macrophage to manipulate iron. BACH1, NRF2, and SPIC are the main transcription factors implicated in the regulation of the expression of heme oxygenase-1 and ferroportin. Insufficient adaptation of the metabolism of the cell to neutralize lipid peroxides leads to iron-dependent programmed lytic death, called ferroptosis. As a result of ferroptosis, damage-associated molecular patterns and lipid peroxides are released, activating the neighboring immune cells and triggering inflammation. Erythrophagocytosis-induced ferroptosis has been recognized as a main mechanism eliciting the metabolism dysfunction associated with steatohepatitis, atherosclerosis, uremia, and other pathogenic states. A better understanding of the molecular mechanisms implicated in the process could bring forward potential novel therapeutic targets. In this mini-review, the current literature is summarized with regard to the immunometabolic mechanisms that mediate erythrophagocytosis-induced ferroptosis and inflammation.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144031033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hematohidrosis: A Rare Case of Blood Sweating.","authors":"Neelam Singla, Aishwarya Rathod, Md Sadique Hussain, Kavita Goyal, R Roopashree, Pooja Bansal, Shivang Mishra, G V Siva Prasad, Haider Ali, Gaurav Gupta","doi":"10.2174/011871529X370285250323162851","DOIUrl":"https://doi.org/10.2174/011871529X370285250323162851","url":null,"abstract":"<p><strong>Background: </strong>Hematohidrosis is an extremely rare condition characterized by the spontaneous exudation of blood through intact skin, often linked to emotional stress and sympathetic nervous system activation. Due to its rarity, many aspects of its pathophysiology remain poorly understood. This case highlights the importance of considering hematohidrosis in the differential diagnosis of unexplained bleeding and emphasizes the role of psychological assessment in its management.</p><p><strong>Case presentation: </strong>A 7-year-old girl from a low-income background presented with a two-month history of recurrent blood oozing from the sweat glands at her elbows, knee joints, and forehead. The episodes, lasting 5-10 minutes, were more frequent during periods of emotional distress. Physical examination revealed no signs of trauma, purpura, or underlying skin lesions. Routine laboratory investigations, including hemogram, platelet count, clotting time, prothrombin time, and activated partial thromboplastin time, were within normal limits. Microscopic analysis of the secreted fluid confirmed the presence of erythrocytes, supporting the diagnosis of hematohidrosis. Given the suspected psychogenic trigger, the patient was referred for psychiatric evaluation and stress management therapy, leading to a gradual reduction in symptom frequency over a four-month follow- up period.</p><p><strong>Conclusion: </strong>This case reinforces the multidisciplinary approach required for diagnosing and managing hematohidrosis, which lacks definitive diagnostic markers. Early psychological intervention is crucial in mitigating symptom severity, as evidenced by this patient's clinical improvement. Increased awareness of hematohidrosis among clinicians can prevent unnecessary invasive testing, facilitate timely recognition, and optimize patient outcomes.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144048467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Single Nucleotide Polymorphisms and Other Mechanisms on Aspirin Resistance.","authors":"Natalia Sergeevna Nuzhdina, Aleksei Vitalievich Kurguzov, David Sergeevich Sergeevichev","doi":"10.2174/011871529X361464250319084053","DOIUrl":"https://doi.org/10.2174/011871529X361464250319084053","url":null,"abstract":"<p><p>Atherosclerosis and ischemic events play a pivotal role in the pathogenesis of several cardiovascular diseases (CVD). The primary aim of preventing recurrent thrombosis in patients who underwent cardiovascular surgery is the antiplatelet agent administration. Nevertheless, despite the aspirin therapy or double (aspirin plus clopidogrel) therapy, the effectiveness of antithrombotic treatment remains controversial. In recent years, we have learned that some percentage of patients still demonstrate no clinical response to aspirin treatment and may experience a vascular complication. This article provides an overview of recent scientific studies that have focused on experimental detection and genotyping of single nucleotide polymorphisms (SNPs) in patients, involving the main therapeutic target genes: cyclooxygenase COX-1 and COX-2, guanylate cyclase GUCY1A3, the glycoprotein complex GPIIb-IIIa, and the platelet receptor protein PEAR1.\" The aspirin resistance (AR) ranges considerably from 0 % to 66% in patients with ischemic heart disease (IHD) and relatively healthy people (control group). SNP distribution analysis has been proposed to explain the inadequate high platelet reactivity (HPR) among patients with IHD under aspirin treatment. Various SNPs have been proposed to explain the development of CVD and the persistent HPR under aspirin treatment widely used in the prevention of recurrent cardiovascular thrombotic events. Meanwhile, the efficacy of aspirin therapy in secondary thrombosis prevention in patients with IHD is not strongly associated with known SNP. The inconsistent results of different AR clinical trials are likely due to the design of the experiments and methodological and quantitative issues; therefore, careful interpretation of the SNP genotyping results is necessary.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Tale of Triumph: Overcoming Challenges in Surgical ASD Closure for a Patient with Warm AIHA.","authors":"Nicodemus N Triatmojo, Valerinna Yogibuana Swastika Putri, Anna Fuji Rahimah, Gracelia Ruth Elizabeth Damanik, Koernia Kusuma Wardhana","doi":"10.2174/011871529X366103250311061025","DOIUrl":"https://doi.org/10.2174/011871529X366103250311061025","url":null,"abstract":"<p><strong>Background: </strong>Autoimmune hemolytic anemia (AIHA) is a rare disorder in hematology, with an incidence of 1-3 per 100,000 per year. The current data available on open-heart procedures in patients with AIHA is limited. Despite presenting periprocedural challenges, multidisciplinary efforts enabled the successful performance of surgical atrial septal defect (ASD) closure in a patient with warm-reactive AIHA.</p><p><strong>Case presentation: </strong>A 56-year-old woman with a large elliptical ASD was planned for surgical closure. The patient has never received a blood transfusion or experienced any previous hematological issues. During the surgical preparation, the patient's immunoglobulin G Coombs test result was positive for the presence of immunoglobulin G. The patient was diagnosed with a remission state of warm AIHA. A challenge arose when surgical ASD closure needed a cardiopulmonary bypass (CPB), which increased the risk of hemolysis. The patient also needed to be hypothermic to reduce metabolism, which may interact with the pathophysiology of AIHA. Several approaches were taken, and the procedure was conducted successfully without noteworthy obstacles.</p><p><strong>Conclusion: </strong>A successful surgical ASD closure was performed in a patient with complete remission of warm-reactive AIHA. Considering the different hemolytic mechanisms between CPB and AIHA, determining whether AIHA is cold or warm reactive is crucial for managing temperature in the heart-lung machine. Several approaches, such as utilizing a roller pump, a heparin-coated circuit, and administering steroids, can be implemented to prevent hemolysis.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143672004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Green Path to Liver Health: Herbal Solutions for Non-alcoholic Steatohepatitis.","authors":"Shubham Sharma, Anjali Sharma, Parul Gupta, Deepshi Arora, Geeta Deswal, Ajmer Grewal, Devkant Sharma","doi":"10.2174/011871529X360903250211101856","DOIUrl":"https://doi.org/10.2174/011871529X360903250211101856","url":null,"abstract":"<p><p>Non-alcoholic steatohepatitis (NASH) is a progressive liver disease marked by inflammation and fibrosis, stemming from non-alcoholic fatty liver disease (NAFLD). Despite its rising predominance, current therapeutic medications are limited in efficacy and safety. Recent attention has shifted towards herbal therapies as potential adjuncts or alternatives in NASH management, given their anti-inflammatory, antioxidant, and phospholipid-controlling characteristics. This research study attempted to assess critically existing literature on the efficacy of herbal interventions while managing NASH. The main goal was to assess the possible medicinal advantages of different herbs, highlight their mechanisms of action, and identify gaps in current research to guide future studies. A systematic review of peer-reviewed articles using databases, like PubMed, Scopus, and Google Scholar, was conducted. It included studies that investigated the effects of herbal extracts (e.g., silymarin, curcumin, berberine) on NASH-related outcomes, such as liver function, fibrosis, lipid metabolism, and inflammatory markers. The review identified several herbs with promising therapeutic effects on NASH. Silymarin showed consistent improvements in liver enzymes and fibrosis markers. Curcumin and berberine were effective in reducing inflammation of the liver and oxidative damage. However, the heterogeneity in research designs, dosages, and outcome measures has limited the generalizability of findings. Herbal therapies hold potential as complementary treatments for NASH, with evidence supporting their role in improving liver function and reducing inflammation. To prove their safety and effectiveness, however, greater sample numbers and longer follow-up times are required in standardised clinical studies.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Challenges of Polyneuropathy, Organomegaly, Endocrinopathy, M-protein, and Skin Changes (POEMS) Syndrome: A Rare Case Report and Review of the Literature.","authors":"Kailash Kumar, Rohit Daga, Jitendra Singh, Nilesh Kumar, Anju Dinkar","doi":"10.2174/011871529X352283250305042317","DOIUrl":"https://doi.org/10.2174/011871529X352283250305042317","url":null,"abstract":"<p><strong>Introduction: </strong>POEMS syndrome is a rare multisystem disorder associated with plasma cell dyscrasia and abnormal cytokine production, including vascular endothelial growth factor (VEGF). The mandatory criterion for its diagnosis includes polyneuropathy and monoclonal plasma cell disorder, along with other major and minor criteria. This case highlights the diagnostic and therapeutic challenges of POEMS syndrome by depicting the case of a 61-year-old male with progressive sensory-motor polyneuropathy, lymphadenopathy, and splenomegaly.</p><p><strong>Case presentation: </strong>The patient presented with a year-long history of bilateral limb weakness and sensory disturbances, accompanied by abdominal distention, weight loss, and other systemic symptoms. Clinical examination revealed skin hyperpigmentation, splenomegaly, and a right axillary lymph node enlargement. Neurological evaluation showed distal limb hypotonia, absent reflexes, and sensory deficits. Diagnostic investigations, including nerve conduction studies, imaging, and bone marrow biopsy, confirmed POEMS syndrome based on polyneuropathy, monoclonal IgG lambda plasma cells, Castleman disease, sclerotic bone lesions, elevated VEGF, and minor criteria, such as endocrinopathy and skin changes. The treatment comprised lenalidomide and dexamethasone, resulting in significant improvement at the three-month follow-up, including normalized VEGF levels and resolution of ascites.</p><p><strong>Conclusion: </strong>This case highlights the necessity of identifying the many presentations of POEMS syndrome for prompt diagnosis and treatment. Despite its rarity and diagnostic complexity, prompt treatment can significantly improve clinical outcomes. POEMS syndrome should be considered in patients with unexplained neuropathy and systemic features, enabling better outcomes through targeted therapies.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143722740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treating Cardiovascular Disorders with Personalized Medicine.","authors":"Ishu Garg, Harish Kumar, Madhu Verma, Iti Chauhan, Vishal Panwar","doi":"10.2174/011871529X361429250215190129","DOIUrl":"https://doi.org/10.2174/011871529X361429250215190129","url":null,"abstract":"<p><p>The past decade has appreciated personalized medicine as a novel medical approach that deals with all practices that are tailored to individual patients. Personalized treatment or personalized cardiology for cardiovascular disorders is an emerging medicine system for related patients. Personalized cardiology is solely based on genomics and proteomics; molecular diagnostics and biomarkers of the cardiovascular system link diagnosis with therapy. Bioinformatics is useful in CVD risk stratification and might improve risk-estimating algorithms. Personalized cardiology involves 3D printing, pharmacotherapy, surgery, lifestyle modifications, and combinations thereof. Understanding the pathology of CVD and identifying causative factors at the individual level can provide opportunities for developing personalized medicine. Since it offers novel avenues for diagnosing, preventing, and treating CVD, molecular genetics has made a substantial contribution to the field of molecular cardiology. Nonetheless, there are still a lot of obstacles to overcome from the standpoints of science and policy. These obstacles can be avoided using evidence-based procedures, clinical applications, biomarker-based detection techniques, comprehensive concepts, and understanding. Targeted therapies may be developed as a result of improved disease classification and a better knowledge of the individual differences in pathology. Cardiovascular disorders, like hypertension, angina, or ischemic heart, a condition of reduced blood flow to the heart, coronary artery disease or damaged blood vessels, myocardial infarction or resisted blood flow to the myocardium, and cardiac arrhythmia or irregular cardiac cycles are the primary targets for personalized cardiology. The current review discusses various parameters for personalizing the treatment of cardiovascular disorders.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}